Goldman Sachs
WINT

Goldman Sachs’s Windtree Therapeutics WINT Stock Holding History

Goldman Sachs’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-247
Closed -$4.3K – 6428
2024
Q4 		$4.3K Buy
+247
New +$7.84K ﹤0.01% 5958
2021
Q3 		– Sell
-1
Closed -$153K – 6544
2021
Q2 		$153K Buy
+1
New +$97.3K ﹤0.01% 5844
2020
Q4 		– Hold
0
– -$60K – 5724
2020
Q3 		– Hold
0
– – – 5162

Other funds holding WINT

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Goldman Sachs's WINT Position: Q1 2025 in Review

Goldman Sachs sold out of Windtree Therapeutics (WINT) in Q1 2025, closing a stake of 247 shares — an estimated $4.3K sold.

Goldman Sachs first reported a position in WINT in Q2 2021 and held it in 2 quarters. The position peaked at $153K in Q2 2021. 5 funds tracked by Wall St. Rank hold WINT as of Q1 2025.

  • Goldman Sachs reported no remaining Windtree Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 247 Windtree Therapeutics shares in Q1 2025, an estimated $4.3K.
  • Goldman Sachs first reported a position in Windtree Therapeutics in Q2 2021 and held it in 2 quarters.
  • Goldman Sachs's Windtree Therapeutics position peaked at $153K in Q2 2021.
  • 5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.